Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study
Continuous OCR treatment results in increasing hypogammaglobulinemia associated with increasing risk of moderate and severe infections. The clinical significance of these immunological findings and the influences of demographic characteristics highlight the importance of regular, personalized immunoglobulin monitoring during long-term OCR therapy.
Authors
- Amanda Baker (ORCID: https://orcid.org/0000-0002-0291-707X)
- Sergey Tarima (ORCID: https://orcid.org/0000-0001-7542-1094)
- Toni Perea
- Pamela Van Zealand
- B. Khatri (ORCID: https://orcid.org/0009-0009-6477-181X)
- S Schutten
Institutions
- Ascension (US)
- University of Kentucky (US)
- St. Francis Hospital (US)
Publication Details
- Journal
- Multiple Sclerosis Journal - Experimental Translational and Clinical
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/20552173251391975
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00